Payment overview · 2025
General Payments
$89.34
5 reported records · 5 companies
Healthcare provider profile · identity verified
Andres Botero, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JENKINTOWN, PA · NPI 1902996309
Verified facts
What the public records show
CMS Open Payments records show Andres Botero, MD received $89.34 in general payments during 2025 across 5 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.74 | 25.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.91 | 20.1% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $16.95 | 19.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.24 | 18.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.50 | 17.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $89.34 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
280 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 581 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 83 |
| Losartan Potassium | Losartan Potassium | 314 | 78 |
| Gabapentin | Gabapentin | 302 | 66 |
| Omeprazole | Omeprazole | 285 | 70 |
| Eliquis | Apixaban | 280 | 40 |
| Lisinopril | Lisinopril | 263 | 67 |
| Furosemide | Furosemide | 240 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 46 |
| Metformin Hcl | Metformin Hcl | 161 | 33 |
| Simvastatin | Simvastatin | 157 | 45 |
| Potassium Chloride | Potassium Chloride | 140 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 33 |
| Warfarin Sodium | Warfarin Sodium | 130 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 116 | 32 |
| Mirtazapine | Mirtazapine | 115 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 52 |
| Metformin Hcl Er | Metformin Hcl | 112 | 34 |
| Tramadol Hcl | Tramadol Hcl | 104 | 31 |
| Donepezil Hcl | Donepezil Hcl | 102 | 23 |
| Trazodone Hcl | Trazodone Hcl | 96 | 26 |
| Lorazepam | Lorazepam | 95 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 21 |
| Finasteride | Finasteride | 80 | 16 |
| Valsartan | Valsartan | 79 | 24 |
| Famotidine | Famotidine | 77 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 18 |
| Synthroid | Levothyroxine Sodium | 67 | 20 |
| Jardiance | Empagliflozin | 66 | 11 |
| Carvedilol | Carvedilol | 65 | 18 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Spironolactone | Spironolactone | 65 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 29 |
| Allopurinol | Allopurinol | 64 | 19 |
| Prednisone | Prednisone | 64 | 39 |
| Atenolol | Atenolol | 61 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 15 |
| Januvia | Sitagliptin Phosphate | 57 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 11 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Bumetanide | Bumetanide | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | 15 |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Nifedipine Er | Nifedipine | 52 | 11 |
| Ezetimibe | Ezetimibe | 49 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 16 |
| Glipizide Er | Glipizide | 44 | 11 |
| Labetalol Hcl | Labetalol Hcl | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 18 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 40 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 15 |
| Xarelto | Rivaroxaban | 38 | 11 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Cephalexin | Cephalexin | 34 | 24 |
| Digoxin | Digoxin | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 17 |
| Repaglinide | Repaglinide | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Glipizide | Glipizide | 28 | 11 |
| Meloxicam | Meloxicam | 28 | 13 |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 14 |
| Metolazone | Metolazone | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Restasis | Cyclosporine | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89.34 · 5 records | Bayer Healthcare Pharmaceuticals Inc. | GLYCATE, Kerendia, MYFEMBREE, NURTEC ODT, OTEZLA, PAXLOVID, RELTONE 200 MG, RELTONE 400 MG, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error